Trials / Completed
CompletedNCT03029234
Carfilzomib in Combination With Dexamethasone (Kd) in Chinese Patients With Relapsed & Refractory Multiple Myeloma
An Open-label, Single-arm, Phase 3 Study of Carfilzomib in Combination With Dexamethasone in Subjects With Relapsed and Refractory Multiple Myeloma in China
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 126 (actual)
- Sponsor
- Amgen · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to evaluate the safety, tolerability and overall response rate of carfilzomib in combination with dexamethasone for the treatment of multiple myeloma in China.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexamethasone | 20 mg intravenous (IV) or oral dexamethasone on days 1, 2, 8, 9, 15, 16, 22, and 23 in 28-day cycles. |
| DRUG | Carfilzomib | Infusion of IV carfilzomib on days 1, 2, 8, 9, 15 and 16 in each 28-day cycle. |
Timeline
- Start date
- 2017-03-31
- Primary completion
- 2018-11-05
- Completion
- 2021-06-04
- First posted
- 2017-01-24
- Last updated
- 2022-05-25
- Results posted
- 2019-11-21
Locations
17 sites across 1 country: China
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03029234. Inclusion in this directory is not an endorsement.